Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.

Leucht S, Barabássy Á, Laszlovszky I, Szatmári B, Acsai K, Szalai E, Harsányi J, Earley W, Németh G.

Neuropsychopharmacology. 2019 Mar 5. doi: 10.1038/s41386-019-0363-2. [Epub ahead of print]

PMID:
30836381
2.

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.

Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G.

Eur Psychiatry. 2019 Feb 7;58:1-9. doi: 10.1016/j.eurpsy.2019.01.015. [Epub ahead of print]

3.

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.

Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S.

Eur Neuropsychopharmacol. 2019 Jan;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008. Epub 2018 Nov 20.

4.

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Németh G.

Int Clin Psychopharmacol. 2018 Nov;33(6):312-321. doi: 10.1097/YIC.0000000000000235.

5.

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis.

Durgam S, Earley W, Lu K, Németh G, Laszlovszky I, Volk S, Litman RE.

Int J Clin Pract. 2017 Dec;71(12). doi: 10.1111/ijcp.13037. Epub 2017 Nov 9. Review.

6.

Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder.

Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, Yatham LN.

J Affect Disord. 2018 Jan 15;226:239-244. doi: 10.1016/j.jad.2017.09.040. Epub 2017 Sep 25.

7.

The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.

Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G.

J Affect Disord. 2018 Jan 1;225:350-356. doi: 10.1016/j.jad.2017.08.040. Epub 2017 Aug 18.

8.

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.

Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S.

BMC Psychiatry. 2017 Aug 24;17(1):305. doi: 10.1186/s12888-017-1459-z.

9.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.

Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM.

Int Clin Psychopharmacol. 2017 Nov;32(6):319-328. doi: 10.1097/YIC.0000000000000187.

10.

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.

Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G.

CNS Spectr. 2018 Feb;23(1):39-50. doi: 10.1017/S1092852917000220. Epub 2017 May 8.

PMID:
28478771
11.

Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-271].

Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Wolfgang Fleischhacker W, Nasrallah HA.

Schizophr Res. 2018 Feb;192:493. doi: 10.1016/j.schres.2017.04.020. Epub 2017 Apr 18. No abstract available.

PMID:
28427929
12.

Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.

Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN.

J Affect Disord. 2017 Jun;215:205-212. doi: 10.1016/j.jad.2017.03.032. Epub 2017 Mar 9.

13.

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.

Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW.

Lancet. 2017 Mar 18;389(10074):1103-1113. doi: 10.1016/S0140-6736(17)30060-0. Epub 2017 Feb 7. Erratum in: Lancet. 2017 Mar 18;389(10074):1102.

PMID:
28185672
14.

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.

Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S.

Psychopharmacology (Berl). 2017 Jan;234(2):199-209. doi: 10.1007/s00213-016-4450-3. Epub 2016 Nov 2.

15.

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.

16.

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.

Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA.

Schizophr Res. 2016 Oct;176(2-3):264-271. doi: 10.1016/j.schres.2016.06.030. Epub 2016 Jul 15. Erratum in: Schizophr Res. 2018 Feb;192:493.

17.

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.

Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, Fava M, Montgomery SA.

J Clin Psychiatry. 2016 Mar;77(3):371-8. doi: 10.4088/JCP.15m10070.

18.

The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials.

Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I.

J Clin Psychiatry. 2016 Jan;77(1):109-15. doi: 10.4088/JCP.15m10192.

19.

Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.

Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY.

J Clin Psychiatry. 2015 Dec;76(12):e1574-82. doi: 10.4088/JCP.15m09997.

20.

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.

Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I.

Int Clin Psychopharmacol. 2016 Mar;31(2):61-8. doi: 10.1097/YIC.0000000000000110.

21.

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.

Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, Vieta E, Calabrese JR, Yatham LN.

Am J Psychiatry. 2016 Mar 1;173(3):271-81. doi: 10.1176/appi.ajp.2015.15020164. Epub 2015 Nov 6.

PMID:
26541814
22.

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.

Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S.

J Clin Psychopharmacol. 2015 Aug;35(4):367-73. doi: 10.1097/JCP.0000000000000346.

PMID:
26075487
23.

Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study.

Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S.

J Clin Psychiatry. 2015 Mar;76(3):284-92. doi: 10.4088/JCP.14m09081.

24.

Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.

Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S.

J Affect Disord. 2015 Mar 15;174:296-302. doi: 10.1016/j.jad.2014.11.018. Epub 2014 Nov 24.

25.

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.

Bipolar Disord. 2015 Feb;17(1):63-75. doi: 10.1111/bdi.12238. Epub 2014 Jul 24.

26.

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.

Schizophr Res. 2014 Feb;152(2-3):450-7. doi: 10.1016/j.schres.2013.11.041. Epub 2014 Jan 10.

27.

Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.

Tóth M, Varrone A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B.

Synapse. 2013 May;67(5):258-64. doi: 10.1002/syn.21631. Epub 2013 Feb 8.

PMID:
23238770
28.

Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.

Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt E, Kiss B, Vastag M, Tihanyi K, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Kapás M, Szombathelyi Z.

Bioorg Med Chem Lett. 2012 May 15;22(10):3437-40. doi: 10.1016/j.bmcl.2012.03.104. Epub 2012 Apr 4.

PMID:
22537450
29.

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B.

Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28.

30.

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z.

J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21.

PMID:
20093397
31.

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Agai-Csongor E, Domány G, Szombathelyi Z.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):515-28. doi: 10.1007/s00210-008-0308-5. Epub 2008 Jun 13.

PMID:
18551280
32.

Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.

Agai-Csongor E, Nógrádi K, Galambos J, Vágó I, Bielik A, Magdó I, Ignácz-Szendrei G, Keseru GM, Greiner I, Laszlovszky I, Schmidt E, Kiss B, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Domány G.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5340-4. Epub 2007 Aug 15.

PMID:
17720494
33.

Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.

Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z.

J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78. Epub 2006 Dec 14.

PMID:
17170312
34.

Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756.

Sóvágó J, Farde L, Halldin C, Schukin E, Schou M, Laszlovszky I, Kiss B, Gulyás B.

Brain Res Bull. 2005 Oct 15;67(3):219-24.

PMID:
16144658
35.

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats.

Laszy J, Laszlovszky I, Gyertyán I.

Psychopharmacology (Berl). 2005 May;179(3):567-75. Epub 2004 Dec 24.

PMID:
15619116
36.

Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain.

Sóvágó J, Farde L, Halldin C, Langer O, Laszlovszky I, Kiss B, Gulyás B.

Neurochem Int. 2004 Oct;45(5):609-17.

PMID:
15234102
37.

Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands.

Laszlovszky I, Acs T, Kiss B, Domány G.

Pharmazie. 2001 Apr;56(4):287-9.

PMID:
11338664
38.
39.

Analysis of the mesotelencephalic dopamine system by quantitative-trait locus introgression.

Vadasz C, Sziraki I, Sasvari M, Kabai P, Murthy LR, Saito M, Laszlovszky I.

Neurochem Res. 1998 Nov;23(11):1337-54.

PMID:
9814544
40.

Genomic characterization of two introgression strains (B6.Cb4i5) for the analysis of QTLs.

Vadász C, Sziraki I, Sasvari M, Kabai P, Laszlovszky I, Juhasz B, Zahorchak R.

Mamm Genome. 1996 Jul;7(7):545-8. No abstract available.

PMID:
8672137
41.

Transfer of brain dopamine system-specific quantitative trait loci onto a C57BL/6ByJ background.

Vadász C, Sziráki I, Murthy LR, Sasvári-Székely M, Kabai P, Laszlovszky I, Fleischer A, Juhász B, Zahorchak R.

Mamm Genome. 1994 Nov;5(11):735-7. No abstract available.

PMID:
7873887
42.

Genetic aspects of dopamine receptor binding in the mouse and rat brain: an overview.

Vadasz C, Laszlovszky I, De Simone PA, Fleischer A.

J Neurochem. 1992 Sep;59(3):793-808. Review. No abstract available.

PMID:
1494909
43.

Spike-and-wave neocortical patterns in rats: genetic and aminergic control.

Buzsáki G, Laszlovszky I, Lajtha A, Vadász C.

Neuroscience. 1990;38(2):323-33.

PMID:
2263319
44.

Substituted ergolines: potential antipsychotics with unique profile. II. Neurochemical characterization.

Auth F, Kiss B, Laszlovszky I, Lapis E.

Pol J Pharmacol Pharm. 1988 Nov-Dec;40(6):603-11.

PMID:
2479935
45.

Characterization of beta-adrenergic receptors in rat ovary.

Laszlovszky I, Erdö SL.

Eur J Pharmacol. 1983 Dec 9;96(1-2):101-4.

PMID:
6141056

Supplemental Content

Loading ...
Support Center